ÂÜÀòÂÒÂ×

Roger Moody was appointed chief executive officer of the Company effective as of 24 April 2023.

Mr. Moody has more than 30 years of experience in the technology and healthcare industry and brings a unique combination of deep knowledge of molecular diagnostics in the US and a proven track record of scaling up public companies.

He has held various senior executive positions leading strategic business development, scaling manufacturing and commercial operations and securing funding in both private and public offerings.

Prior to joining Biocartis, Mr. Moody served as CEO of GlySure Limited, whose primary assets were sold to Baxter International (NYSE: BAX), and held the CFO position at Nanosphere (now part of DiaSorin (Euronext Milan: DIA), Clinical Genomics, Inc., a colorectal cancer diagnostics company) and most recently Talis Biomedical (Nasdaq: TLIS), a point-of-care molecular diagnostics company.